Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
News Release Digital Asset Direct

Meet Your Friendly Neighborhood Knightscope Robot

Benzinga

By Faith Ashmore, Benzinga Click here to learn more about the Knightscope Public Safety Infrastructure Bond. For many decades, people have been imagining how robots would fit into the future. Whether it was Sonny from Isaac Asimov’s I, Robot, the equally awe-inspiring and terror-inducing Terminator, or everyone’s favorite Wall-E, robots have been a part of pop culture for decades. Well, now robots are no longer a thing solely reserved for Hollywood. And better yet, they are helping keep the streets safe without the risk of going rogue. The future is now. In an ever-evolving world, public safety is in need of an upgrade. AI and robotics are part of the solution to create safer public spaces while decreasing human error that can come from human police officers. Knightscope (NASDAQ: KSCP) is a technology company ushering in the dawn of Autonomous Security Robots (ASRs) and working hard to protect U.S. citizens from crime across the country. The company has over a decade of experience and has shown its solutions to be effective. For example, when one of its units was deployed in Huntington Park, Los Angeles County, there were 46% fewer crime reports overall – and they have recently renewed the contract for the 5th year in a row. Knightscope’s success has garnered national attention, and the company has won corporate contracts with major corporations such as PENN Entertainment (NASDAQ: PENN), PG&E (NYSE: PCG), ABM (NYSE: ABM) and Lowe's (NYSE: LOW) The company’s robots are designed to enhance safety and security in various environments, such as corporate campuses, shopping malls and hospitals. Knightscope robots operate autonomously, meaning they can navigate and patrol areas without human intervention. They utilize a combination of sensors, cameras and artificial intelligence algorithms to detect and analyze their surroundings in real time. The robots are equipped with 360-degree cameras, thermal imaging sensors, and license plate recognition capabilities to capture and analyze visual data. They can also detect signals from Wi-Fi and Bluetooth devices, helping to identify potential security threats. The data collected by the Knightscope robots is sent to a central command center through a secure wireless network. The command center operators can monitor the robot's feed, receive alerts for suspicious activity, and control the robot's movements remotely when necessary. The robots were also designed with a large physical presence to serve as a deterrent, as their presence often helps to discourage criminal activity. Knightscope’s influence and reach seem to be on the rise. Just in 2023, the company has made more than 50 announcements including numerous contracts and reports it is on track to double its revenue versus 2022. These contracts further validate the growing demand for Knightscope's robotic solutions as they continue to work through a nearly $5 million backlog of new orders.. The company is also joining the NYPD and MTA in New York City. Their robots will operate within the subway system during the late-night hours of 12:00 a.m. to 6:00 a.m. The K5 robots maintain a balance of effectiveness and approachability, being both engaging and respectful of privacy. Better yet, they were designed to be photogenic, and NYC tourists are sure to get a kick out of the recent development. This deployment signifies the continued expansion of Knightscope's robots to support policing efforts throughout the United States – with the largest city in the country with the largest police department in the country taking the lead Another notable development is the launch of their School Safety Grant Program. This initiative enables individuals to contribute to creating safer learning environments in K-12 schools. By pooling together non-deductible donations, the program aims to partially subsidize schools facing budget constraints, preventing them from implementing Knightscope's advanced security technologies. This endeavor is a powerful way to protect children, faculty, and administrators within educational institutions. The company is currently offering an investment opportunity for interested parties to buy bonds. Over recent years, there has been an increase in the development of robotic technologies for everyday life activities. Positive attitudes towards robots are increasing, and while there are mixed views globally, there is an overall recognition of the potential benefits and positive impact of robot use in society. The demand for robots is only poised to grow. In 2021. The robotics market was valued at $31.38 billion in 2021 and is expected to reach $110.39 by 2030 with a CAGR of 15% from 2022-2030. Knightscope seems well-positioned to capitalize on this growth and be a potential leader in the U.S. market. Click here to learn more about the Rise of the Robots. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2023 09:00 AM Eastern Daylight Time

Starpax’s Cancer Technology Looks To Address A Major Problem That Chemotherapy And Immunotherapy Haven’t Solved For A Century

Benzinga

By Kimberly Adams, Benzinga The human body has healthy cells that reproduce to replace damaged or missing cells in the tissues. Cancer starts when one of those cells begins to have an abnormal reaction that causes it to reproduce perpetually. It takes approximately one billion of these cancer cells to end up with a ¾-inch tumor. So, imagine how many cancer cells a 2-inch tumor gets. If you don’t kill all these cancer cells, a single cancer cell left could cause the cancer to come back. When tumors grow, blood vessels in the tumor begin to malfunction, becoming chaotic and often collapsing. Drugs and immune cells need blood vessels to reach all cancer cells in a tumor, however, unfortunately, there are regions of the tumor where cancer cells are totally inaccessible. These regions are called hypoxic zones – where the level of oxygen is extremely low – and this is where the cancer stem cells are located. It is very important for a cancer treatment to eliminate cancer stem cells because they are the major driver of metastasis in the patient’s body and resistance to treatment. It is well documented that systemic chemotherapy or immunotherapy fails to reach hypoxia zones to kill cancer stem cells. The reason is simple – if there are no blood vessels to bring drugs or immune cells next to a cancer cell, the counter-tumor action cannot work because drugs or immune cells are not self-propelled to travel by themselves in the interstitial spaces of the tumor tissues. Of course, when the blood vessels in a tumor are not too damaged and hypoxic zones are still absent, patients see treatments showing some efficacy. But the problem is that cancer diagnostics often come too late and hypoxic zones are too often already present in the tumor at the patient’s first exam. This is where Starpax’s never-before-seen extraordinary technology comes in – to address specifically this problem of reaching cancer cells in hypoxic zones. Starpax Magnetodrones™ are self-propelled, meaning they can swim in the interstitial space of tumor tissues without the need for blood vessels. The Magnetodrones are proprietary nonpathogenic Starpax living bacteria (Bn1-S™) developed in-laboratory, conceived to transport FDA-approved anticancer molecules attached to their surface. They are injected directly into the tumor, not in the blood vessels. They are sensitive to very special magnetic fields generated by the Starpax Polartrak™, a medical device invented by Starpax in which the patient is installed. The Polartrak creates unique patented virtual monopole magnetic fields vectors that control the trajectory of the Magnetodrones in 3D with millimetric precision inside the tumor in order to force them to spread throughout the whole volume of the tumor while they release drugs to the cancer cells on their path. Also, the PolarTrak is conceived to create a magnetic sphere around the tumor that keeps the Magnetodrones captive inside the tumor, thus aiming to avoid toxicity to the rest of the patient’s body and typical side effects of systemic treatments that could damage healthy tissues and organs. Another specific characteristic of the Magnetodrones is they are aerotactic – that means they search for a low level of oxygen to be comfortable. The Magnetodrones have been developed to live in a culture media with an excessively low oxygen level which is the same as the oxygen level in a hypoxic zone. So, when they pass by a hypoxic zone, they stop swimming, penetrate and accumulate into it to deliver anticancer drug to stem cells inaccessible by current systemic treatments or even immune cells. Since stem cells do not divide in hypoxia zones – The Magnetodrones bring a specific drug molecule into this area that reverses chemoresistance of the hypoxic zones in order to destroy stem cells. Magnetodrones cannot proliferate in the human body as they die within 60 minutes after the injection because the temperature of the human body is too high for them to survive. Having reached 100% remission rate and no side effects observed in their preclinical studies, Starpax is confident of achieving similar results in its human clinical studies scheduled for the end of the first quarter of 2024. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 10, 2023 09:00 AM Eastern Daylight Time

News Release

Vertiqal Studios strengthens position in Australia with appointment of Rifle as agency of record

Vertiqal Studios

Vertiqal Studios CEO Jon Dwyer joined Proactive's Stephen Gunnion with news that the company has appointed Rifle Agency as its agency of record for Australia. The move comes as Vertiqal experiences substantial growth in Australia and New Zealand, where viewer preferences align with those in North America and the UK. The agency will handle both creative video production and distribution across Vertiqal Studios' network. Vertiqal Studios already reaches almost 20% of the Australian audience organically and the partnership aims to strengthen Vertiqal's presence in Australia further. The collaboration between Vertiqal and Rifle Agency is marked by a regionally exclusive white-label partnership, where Rifle will market and sell Vertiqal's creative assets and distribution services. This unique arrangement allows Rifle to leverage Vertiqal Studios' creative expertise and extensive distribution network while offering brands tailored video content and distribution solutions. It's a low-risk strategy for both parties to explore the Australian market and offers exciting growth opportunities. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 09, 2023 01:00 PM Eastern Daylight Time

Video

News Direct Launches "Trade Wins", an Analytics Enhancement Designed to Better Gauge Vertical Media Engagement

News Direct

News Direct today announced Trade Wins, a significant enhancement to its performance analytics that provides users actionable data regarding engagement with news releases from among industry trade media. Unlike legacy newswires which rely on sometimes decades-old internal databases of trade publication contacts, often with limited staff keeping them current, News Direct's partnership with one of the industry’s leading media monitoring and media database platforms enables it to provide up-to-date targeting of key journalists at tens of thousands of publications. News Direct leverages a comprehensive global directly of media contacts to create highly in-depth lists of trade journalists from within hundreds of industry verticals and sub-verticals, which are automatically refreshed to the most recent update each time any category is selected. The platform is then able to deliver meaningful analytics that provide the issuer with open rates, unique opens, total opens, click rates, unique clicks and engagement over time, which forms the basis of Trade Wins reports. The service will be available to all users for $50 per report. “From the beginning, News Direct has aimed to offer users as much useful data as possible to help them understand the impact of their news distribution efforts. Until now, that's been primarily focused on information that can be gathered from digital media and news portals. Trade Wins provides a more granular view of the engagement their content is receiving within the trade media, which for many companies represents the most fertile opportunities for earned media coverage”, observed Gregg Castano, News Direct Founder and CEO. About News Direct News Direct is a technology-driven content distribution and amplification platform for PR, IR, corporate communications and marketing professionals. Our automated platform delivers a completely reimagined, modernized user experience for newswire users that has reshaped the industry landscape. Additionally, the company has expanded its offerings to include an array of technology-enhanced message amplification tools ranging from sponsored content to podcasting products, all from one online destination. Contact Details News Direct Media at News Direct media@newsdirect.com Company Website http://www.newsdirect.com

October 09, 2023 08:17 AM Eastern Daylight Time

Image

Greater Miami Jewish Federation to Hold Israel Solidarity Rally on Tuesday, Oct. 10 from 6-7 p.m. at Holocaust Memorial Miami Beach

Greater Miami Jewish Federation

What: Israel Solidarity Rally community-wide gathering Where: Holocaust Memorial Miami Beach, 1933-1945 Meridian Avenue, Miami Beach, FL 33139 Who: Greater Miami Jewish Federation, its Jewish Community Relations Council, the Rabbinical Association of Greater Miami and other community organizations When: 6 - 7 p.m., Tuesday, October 10, 2023 Why: In the wake of the unprovoked, deadly, multi-front Hamas attacks on Israel, the Greater Miami Jewish Federation will gather the Miami community at the Holocaust Memorial to show solidarity with the people of Israel. Local leaders, clergy and elected officials will speak. Editor’s note: Media credentials will be required. A media platform will be available for cameras. Live trucks can be parked at 19 th Street. English and Spanish interviews will be available. Day of contact: John P. David at 305.724.3903. In addition to the rally, the Greater Miami Jewish Federation has opened an Israel Emergency Fund. Federation is in close contact with its overseas partners and anticipates an unprecedented need for cash to assist victims of terror and their families. As always, Federation will absorb all administrative costs so that 100 percent of funds donated to this emergency campaign will provide critically needed aid to victims and their families. Those wishing to contribute can visit JewishMiami.org/ief or call 305.576.4000. The Mission of the Greater Miami Jewish Federation is to mobilize human and financial resources to care for those in need, strengthen Jewish life and advance the unity, values and shared purpose of the Jewish people in Miami, in Israel and around the world. Contact Details Bonnie Reiter-Lehrer +1 305-798-4422 breiter@gmjf.org John P. David +1 305-724-3903 john@davidpr.com Company Website https://jewishmiami.org/

October 08, 2023 12:04 PM Eastern Daylight Time

Sharps Technology (STSS) To Enter The Copolymer Prefillable Syringe Market With Strength And Ahead of Plan Through Pending Manufacturing Facility Acquisition and $400M Nephron Deal

Benzinga

By Meg Flippin, Benzinga Sharps Technology Inc. (NASDAQ: STSS) is pushing into the copolymer prefillable syringe market thanks to a deal with Nephron Pharmaceuticals Corp., a leader in contract manufacturing of generic medications and 503B outsourcing that includes prefillable sterile syringes. Sharps announced the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility for $50 Million. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for Sharps’ next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033. “With this landmark purchase agreement in place for our copolymer prefillable syringes, we will accelerate the realization of our shared goals, transition the company to revenue, and propel Sharps into a new phase of growth and sustainability,” commented Robert Hayes, CEO of the medical device and pharmaceutical packaging company specializing in developing and manufacturing copolymer drug delivery systems. “At the forefront of our growth trajectory are our copolymer-based prefillable syringe systems, a sector that is experiencing escalating market demand and is poised to shape the future of Sharps.” Owning Manufacturing For A Market Poised For Growth Market research is forecasting significant growth within the prefillable syringe segment, with product demand outstripping supply for the foreseeable future. The market for prefilled syringes is projected to grow at a compound annual growth rate of ~12% from 2022 to 2030, according to Grand View Research. The prefilled syringe market is a niche sub-industry within the healthcare sector and Sharps will serve both Nephron and other customers within the copolymer segment of the market. Contributing to the demand for copolymer-based syringes are the glass-like features without breakage, and the market could be ripe for growth due to the global lack of capacity for these products and technical challenges in production that Sharps’ team reports a wealth of experience in. Under the terms of the deal, Sharps is paying $50 million for the InjectEZ specialty copolymer syringe manufacturing facility, which is one of the only fully dedicated facilities to manufacture these types of syringes in North America. Located on Nephron’s campus in West Columbia, South Carolina, InjectEZ has fully automated prefillable syringe system manufacturing capabilities that utilize ISO cleanrooms for all key areas including injection molding, high-speed automated assembly, and specialty packaging lines that are equipped with Husky molding machines and Hahn automation. With full control of the InjectEZ facility through this transaction and the capacity from the Company’s wholly-owned manufacturing facility in Hungary, Sharps will have the ability to supply Nephron with their prefilled syringe needs and also commercialize products to the broader healthcare syringe market. The company expects the deal to generate “significant” short and long-term revenue. Nephron Inks 10-Year Purchase Agreement As a result of this deal the Company’s first customer will be Nephron, which inked a 10-year purchase agreement for Sharps’ next-generation copolymer prefillable 10 mL and 50 mL syringes. Minimum orders will be over $400 Million during that period. Sharps expects to begin delivering products to Nephron in the first quarter of 2024, representing about $30 million in revenue for the first 12 months of production. Starting in 2025, Sharps expects revenue of at least $45 million per year through 2033 from Nephron, with additional revenue from its capacity to serve the broader market for its products. “As a company that is transitioning from research and development to commercialization, this is a significant development that will have a meaningful impact on Sharps’ revenue and profitability,'' states Mr. Hayes. We anticipate Nephron's start-up volume to be approximately 60% of our initial planned manufacturing capacity, which will provide Sharps with the ability to fully service Nephron’s needs and to also sign purchase orders for our products from other companies in the healthcare market.” To finance the acquisition of InjectEZ, Sharps retained Lampert Capital Advisors, a provider of financing solutions to public and private companies. Lampert is engaged in a financing process that has resulted in a signed term sheet with a leading middle-market lender for up to $75 Million in debt financing to be used for the acquisition of InjectEZ, production line enhancements, working capital, transaction fees and expenses, and general corporate purposes. Continuing Relationships and Growth Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 to support the manufacturing of its innovative prefillable syringe systems. Through the successful completion of the new Asset Purchase Agreement and the 10-year purchase agreement, Sharps is poised to have a full partnership and a U.S. footprint that will provide a strong baseline of revenue for Sharps for many years. The new agreement will leverage synergies from both companies and enable Sharps to commercially enter the prefilled syringe landscape with manufacturing strength and ahead of plan. These developments are the culmination of a strong partnership developed in 2022, and may be just the beginning: “We are excited about the opportunities that lie ahead as we strengthen our relationship with Nephron and will update our shareholders as the transaction advances,” said Mr. Hayes. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 06, 2023 08:50 AM Eastern Daylight Time

Gamelancer announced strategic rebrand going forward as Vertiqal Studios

Gamelancer Media Corp

Gamelancer Media Corp CEO Jon Dwyer joined Steve Darling from Proactive to discussed significant developments within the company, which is undergoing a major strategic rebrand and will now operate as Vertiqal Studios. Dwyer telling Proactive to the key highlights of this transformation. Vertiqal Studios' rebranding is a strategic move to showcase the company's adaptability in navigating the ever-evolving digital media advertising landscape. The new name reflects Vertiqal Studios' commitment to delivering high-performance, brand-centric advertising solutions for its valued clients. Effective October 2, 2023, the company will begin trading as "VRTS" on the Toronto Stock Exchange as part of its corporate rebrand. Dwyer emphasized that the rebrand to Vertiqal Studios will give the company a fresh and dynamic look, particularly as it expands its operations into the US market. The company believes this evolution will not only enhance its presence in the industry but also open up new opportunities for growth and success. Additionally, Dwyer discussed a change on the corporate side, where co-founders Razvan Romanescu and Darren Lopes will remain on the Board of Directors but will step down from their current positions as Chief Strategy Officer and Chief Product Officer. These changes are part of the company's broader efforts to position itself for continued success and growth in the digital media advertising sector. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 05, 2023 10:16 AM Eastern Daylight Time

Video

Minuteman Press Franchise Comes to Poundbury and Dorchester, Moves to Brand New Premises

Minuteman Press International Inc

Sprint Digital, Dorchester's leading small business printers, have successfully completed the transition into a Minuteman Press franchise. Owners David and Juanita Prince have relocated from their town centre premises, shared with the Dorchester Post Office, into their own stand alone premises in Poundbury at 13 & 14 Jubilee Court, Paceycombe Way. David Prince said, “With easy access and free parking, the offices just down from the Buttermarket are well placed for access for our clients. We will also continue to deliver to our existing business customers in Dorchester should they need to ensure a seamless transition for our clients.” Operating for over 50 years to serve local business communities, Minuteman Press International has almost 1000 independently owned and operated franchise locations worldwide. The transition from Sprint Digital to Minuteman Press will give small businesses in Dorchester, Poundbury and its surrounds more access to an extremely wide range of print solutions, from business cards and fliers to small signage, branded promotional items and much more. In response to the rebranding, David and Juanita stated, "The move to Minuteman Press will allow our print business to grow offering the businesses of Dorchester, Poundbury and its surrounds a quality affordable print solution. We are also inviting businesses to shop locally knowing that the product is as environmentally sourced as possible and supported by the expertise of world's leading print franchise.” Mark Jones, Regional VP of Minuteman Press International added, "We are excited to be working with David and Juanita, helping them to grow their franchise whilst supporting the local community with all their print requirements." As part of the conversion David Prince has reaffirmed that MMP Dorchester will take over Sprint Digital's sponsorship of the Dorchester Ladies football team into the 2023/24 season and they will continue to support the developers of Dorchesters Bike Park by providing a range of print solutions for their promotional needs. For more information on Minuteman Press in Dorchester and Poundbury, call 01305 264171 or visit their website: https://minuteman.com/uk/locations/england/dorchester/ Minuteman Press provides digital print, design, promotional products and services to businesses. Today they are much more than just print. They can provide anything you can put a name, image or logo on! Minuteman Press International was once again rated the #1 Printing & Marketing Services Franchise in the printing industry by Entrepreneur Magazine in 2023. This is the 32nd time overall and 20th straight year that they have achieved this stellar rating. Learn more about Minuteman Press franchise opportunities and read Minuteman Press franchise reviews at http://minutemanpressfranchise.co.uk Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

October 05, 2023 09:38 AM Eastern Daylight Time

Image

Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update

Benzinga

By Rachael Green, Benzinga Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, the multi-center clinical trial will have six to ten new clinical trial sites across the US. According to the Company, another key data milestone is expected soon at the ECTRIMS conference, which will detail the results from the expanded access program after six months of treatment. Investors should take note, as this is a significant event for the company through providing six-month clinical results on the second cohort of four patients (numbers 3-6), and also providing a PET scan which shows neuroinflammation in the brain (microglia). ECTRIMS is the world’s largest research meeting in multiple sclerosis and will be held October 11-13 in Milan, Italy. Tiziana also recently announced the acceptance of a publication in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) of its study validating the mechanism of action (MoA) using intranasally administered foralumab in Alzheimer’s disease (AD). The published study concluded that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”, which further supports the Company’s hypothesis for the use of foralumab in neurodegenerative disease. Key highlights from the Journal included: The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s Disease The publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer’s disease by targeting microglial activation in the brain, while expanding regulatory T cells in the periphery Remarkably, this reduced microglial activation and improved cognition occurs independent of amyloid beta disposition. The full publication can be found HERE Tiziana’s Foralumab Is A Promising Treatment With Potential To Treat Multiple Neurological Diseases “The anti-CD3 target is established and it’s validated,” said Tiziana COO and CMO Mathew Davis at a recent conference. “We are the only company that is delivering this intranasally. We are the only company that is in the clinic with a fully human anti-CD3 antibody.” The anti-CD3 monoclonal antibody used in Tiziana’s Foralumab binds to the CD3 receptor on the surface of T cells, typically used as a way to suppress the immune system to prevent transplant rejection or treat autoimmune disease. The challenge in treating these kinds of conditions has long been finding the balance between suppressing the immune response to protect the patient without harming the body’s ability to fight off actual threats like viral infections and bacteria. However, research shows that anti-CD3 antibodies can do just that. They are able to selectively dampen the autoimmune response – when the dysregulated immune system attacks the body’s own cells and tissue – without limiting its ability to detect and respond to external threats. The promising new treatment approach has already sparked interest from pharmaceutical industry leaders like Sanofi SA (NASDAQ: SNY), which just acquired an anti-CD3 therapy being developed for type 1 diabetes in a $2.9 billion acquisition of Provention Bio, Inc. Tiziana’s Foralumab is the only anti-CD3 monoclonal antibody treatment in clinical trials that is fully human — a significant differentiator as these tend to come with fewer adverse reactions than those that are genetically engineered. It’s also the only one that’s delivered via an intranasal spray, making it less invasive than an infusion and allowing it to travel directly to the T cells in the patient’s lymph nodes. In the neurological diseases that Tiziana is focused on, this formulation has allowed its lead drug candidate to bind to regulatory T cells, then these T cells activate and create Tregs which are specifically tasked with maintaining homeostasis and preventing the immune system from attacking itself. Once Foralumab creates these Tregs, they can cross through the blood-brain barrier and help fight neuroinflammation at its source. Tiziana Highlights Past Results And Upcoming Milestones Across Foralumab Clinical Trials During a recent investor conference, Davis focused on the exciting results Tiziana has seen so far from its clinical trials and highlighted some of the upcoming milestones and plans for the year ahead. Its lead program is in non-active secondary progressive multiple sclerosis (SPMS), a more severe stage of the debilitating disease that currently has no FDA-approved treatment. Instead, the standard of care typically involves treating the patient with Ocrelizumab, an anti-CD20 monoclonal antibody sold under the brand name Ocrevus by Genentech, a subsidiary of Hoffmann-La Roche AG (OTCQX: RHHBY). But the drug is not always as effective for SPMS patients as it is for other forms of MS. In fact, Davis noted that all of the patients in its clinical trials had previously tried Ocrelizumab and discontinued it when their symptoms continued to progress. In its ongoing expanded access program, for example, the Tiziana COO and CMO spoke about a patient who had discontinued the anti-CD20 treatment in 2021 when his condition had become so bad that he could no longer walk more than 100 feet without assistance. The non-active SPMS patient enrolled in Tiziana’s expanded access program in January 2022. “By the end of 2022, he was able to walk without assistance,” Davis said. “He’s back in his job and, as of this recording, he continues to walk without assistance.” In the biopharma’s most recent data readout, other patients from the expanded access program started to show similar improvement. Three of the four patients currently enrolled saw their fatigue scores decrease after three months. Meanwhile, a phase 1 trial found that microglia – a part of the innate immune system inside the brain – had significantly decreased activation in the brains of 5 out of 6 treated patients after three months. Davis said another data readout is expected soon, detailing the results from the expanded access program after six months of treatment. Tiziana has begun clinical site selection and plans to start a phase 2a trial in non-active SPMS before the end of this year with topline data expected by the end of 2024. The clinical-stage biopharma is also investigating Foralumab for Alzheimer’s disease (AD), another progressive neurological disease with an urgent need for better treatment options. Tiziana just received FDA approval to begin a phase 2 study in AD, and the company plans to launch that trial in the first half of next year. A press release on the acceptance from the Proceedings of the National Academy of Sciences (PNAS) can be found HERE along with the full publication HERE titled “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”. To learn more about Tiziana, click HERE This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 05, 2023 09:15 AM Eastern Daylight Time

1 ... 71 72 73 74 75 ... 344